Abstract
1082 Background: Nanoparticle albumin-bound-paclitaxel (nab-pac) demonstrated significant antitumor activity in patients with MBC compared with solvent-based paclitaxel. This retrospective analysis evaluated the antitumor activity of nab-pac in patients with MBC who were previously treated with anthracycline, had visceral (lung and/or liver) disease, or had ≥ 3 sites of metastases. Methods: Pts (N = 531) were evaluated from a phase II and a phase III study of nab-pac (Gradishar et al. J Clin Oncol. 2005;23:7794–7803). In the phase III study, pts (including first- and second-line pts) received nab-pac 260 mg/m2 q3w (A) or paclitaxel 175 mg/m2 q3w (B). In the phase II study, first-line pts received nab-pac 300 mg/m2 q3w (C), 100 mg/m2 qw (D), 150 mg/m2 qw (E); or docetaxel 100 mg/m2 q3w (F). Results: See Table. Conclusions: Nab-pac, weekly or every 3 weeks, has significant antitumor activity in patients with MBC regardless of baseline factors (eg, anthracycline use, visceral disease, or ≥ 3 sites of metastasis). Prior anthracycline Pts with visceral disease Pts with ≥3 sites of metastasis Nab-pac 77 77 62 Paclitaxel 78 81 52 Nab-pac 24 81 54 Docetaxel 24 88 59 Overall response rate (%) Overall response rate (%) Overall response rate (%) A* 34 34 26 B* 18 19 17 P-value 0.002 0.002 0.092 C 45 45 46 D 53 61 69 E 68 75 70 F 28 37 29 P-value † 0.062 0.003 0.004 Time to progression/Progression-free survival (months) Time to progression/Progression-free survival (months) Time to progression/Progression-free survival (months) A*‡ 5.3 5.0 4.5 B*‡ 3.8 3.8 3.7 P-value 0.004 0.036 0.053 C 7.9 10.9 10.2 D 7.2 7.5 7.4 E 11.4 13.1 12.9 F 5.5 7.8 7.6 P-value † 0.031 0.242 0.557 Overall survival (months) Overall survival (months) Overall survival (months) A* 14.9 13.1 14.2 B* 12.0 12.3 11.0 P-value 0.049 0.945 0.154 C,D,E,F NA NA NA Pts treated 1st- and 2nd-line; † Comparing nab-pac and docetaxel overall; ‡ TTP in the ph III trial Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Abraxis Bioscience Abraxis Abraxis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.